The Role of Public-Private Partnerships & Evidence Generation
|
|
- Lester Harmon
- 5 years ago
- Views:
Transcription
1 The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created by people affected by the illnesses and diseases we are committed to treating and preventing.
2 Context The value and the need of health data and the journey so far Health data has the potential to change the way we deliver healthcare, shaping future innovation, improving patient outcomes and putting healthcare systems in Europe on a more sustainable path Payers and HTAs, demand real world data in order to grant access to innovative treatments and to engage in outcomes based financing schemes. However, access to this data is still challenging in Europe Growing trend that performance-based schemes will play a relevant role in the pricing of new medicines Only ~60% of European countries with EHR systems and different levels of maturity and coverage of diseases among European registries Several health data initiatives successfully demonstrated the value for Pharma in all the segments of the value chain. However, there is still a need for a scaled-up solution, since initiatives are fragmented in terms of scope, ownership and modalities for data governance
3 Key trends influencing health data Healthcare system trends Technology and innovation trends Evidence needs Payers demand more data to achieve/ maintain reimbursement in addition to classic clinical trial results Big data Rising awareness of the relevance of big data analysis across all sectors for real-time data-driven decision making Pay for outcomes Some payers see potential in linking payments to outcomes achieved Shift to the cloud Scalable processing, Storage & Software as a Service allowing huge capacity and ubiquitous access Patient willingness Patient willingness to share data high in fatal/ pediatric conditions and slowly increasing in other areas Smart devices "Smarter" objects with connection to the Internet, apps and cloud services, low power consumption and faster devices Transparency movement Following clinical trial data sharing debate, calls for observational data transparency can be expected next Cognitive computing Intelligent "AI-like" personalities able to perform complex tasks and offer nuanced recommendations
4 Health data is needed to improve patient health outcomes, HC system sustainability and drive innovation 1 The promise of data for public health is enormous Outcomes data reveals which practices work best and how to improve care quality Outcomes transparency allows informed provider choice Outcomes-driven healthcare could avoid up to deaths in Europe p.a. 2 Data is necessary to achieve sustainable healthcare Outcomes data can identify ineffective practices, reducing cost of care and waste, freeing up resources for innovation Better care leads to fewer complications and follow-on cost Economic value of outcomes-driven healthcare is 60-80bn in Europe p.a. 3 Data is a key success factor for innovation New types and sources (i.e. smart devices, wearables) of health data stimulate innovation in healthcare Identification of patient sub-populations and focussing of research efforts on their specific characteristics Many EFPIA flagship initiatives rely heavily on access to health data
5 Growing trend suggesting performance-based schemes will play an important role in the pricing of new medicines France UK Pricing contracts are reviewed every five years to assess the performance of new medicines in real life settings Through the Early Access Medicines Scheme, the UK is actively exploring how to accelerate pre-approval regulatory pathways and how this can then be integrated into commissioning decisions by the NHS Italy Comprehensive infrastructure of patient registries for cancer care that allows an almost personalized reimbursement of new oncology drugs on the basis of actual patient response This system has resulted in prices that are more affordable, accelerated approval times and improved patient access Source: Paying for outcomes, 2016, EFPIA
6 However, generation and access to RWD still challenging in Europe... EHR Registries Only ~60% of European countries with a EHR systems Different levels of maturity and coverage of diseases among European registries "59 per cent (27 countries) report having a national EHR system" World Health Organization % of Member States using available national EHR systems in >50% of health care facilities Primary care Clinics Health Care centers 60 Secondary care Hospitals Emergency Care centers 55 Tertiary care Specialised Care centers DISEASE GROUP Incl. registries identified by ICHOM for collaboration No of registries Coronary artery dis. 10 Colorectal cancer 6 Hip osteoarthritis 5 Breast cancer 4 Cerebrovascular dis. 4 Knee osteoarthritis 4 Chronic kidney dis. 3 Leukemia & lymphoma 3 Lung cancer 3 Cataract 2 Chronic back pain 2 COPD 2 Dementia 2 Depression 2 Diabetes 2 Schizophrenia 1 No of registries Source: World Health Organisation "From innovation to implementation. ehealth in the European Region", 2016; ICHOM
7 Need for public-private collaboration To work and connect with real world data is necessarily collaborative and multidimensional in challenges In an increasing value and outcome-focused domain in healthcare, evidence is the critical enabler to an informed process of care delivery and optimal outcomes for patients There are many and varied actors in this Building on IMI1 programmes, e.g. EHR4CR, EMIF, ADVANCE, GetReal and other programmes, EFPIA is attempting to utilise the outputs of those PPPs, the relationships and their contributions There is a complex relationship between data custodians and data users, 80% of which is sociological, and 20% technological In IMI2 a new call, the EHDN will be supporting the PPP BD4BO initiative programmes Not one data source is the whole truth in the real world
8 Public Private Partnerships Are Critical To Solving The Challenges
9 The Innovative Medicines Initiative: the largest public-private partnership for health research worldwide 5 billion 2008 to 2024 Part of the EU Horizon 2020 R&D funding
10 IMI Has Delivered Across A Broad Spectrum Of The Pharma Value Chain DISCOVERY New lines of enquiry in drug development (thanks to large data sets) Identification of new hits and leads (screening center with proprietary compounds) First human Beta cell line for diabetes research Regulatory qualified safety biomarkers Computer predictive models for safety Novel approaches in toxicology de-risked EARLY DEVELOPMENT
11 IMI Has Delivered Across A Broad Spectrum Of The Pharma Value Chain LATE DEVELOPMENT Definition of regulatory endpoints. e.g. for autism. geriatric research. asthma. pain Development of antibiotics (new compounds, new formulations) Development of Ebola vaccines and diagnostics (clinical trials, manufacturing, diagnostics, deployment) Clinical trial infrastructure and fast-fail cohorts (pediatrics, antimicrobial resistance, autism) PATIENT ACCESS Definition of evidentiary standards for pragmatic trials Defining and measuring outcomes relevant for and aligned between patients, payers, regulators Progress in de-risking adaptive models based on real world evidence Integration of patient voice in benefit risk evaluations Methodological standards in Pharmacovigilance adopted by regulators
12 IMI Has Supported Key Projects
13 IMI Benefits for Pharma (in general) Stimulates interaction between pharmaceutical companies and academic institutions and SMEs in order to remove bottlenecks in drug discovery and development Free Access for research use to all project results cost efficient way of having precompetitive research done Provides forum for influencing development of regulations and guidelines by regulatory bodies Knowledge sharing and networking opportunities Enables evidence generation on a much larger scale 13
14 IMI The non-tangible benefits Proof of concept for new public private collaborations in pharmaceuticals - today the largest PPP in healthcare research IMI has driven the development of innovative collaboration models supporting unprecedented data and knowledge sharing, maximizing investment already made in R&D and delivering Regulators, health technology assessment agencies and patient groups all play pivotal roles in many projects leading to the generation of solutions acceptable to our major stakeholders A neutral platform for dialogue defining common agenda/priorities (participation of regulators, payers, patients, academia, SMEs) IMI works: tangible deliverables after less than 2 years a pace that no other funding scheme allows 14
15 IMI - Results beyond the state of the art Established robust validated models for Alzheimer, diabetes, schizophrenia, asthma, haematological malignancies, cardiovascular disease. Developed clinically relevant biomarkers for Alzheimer, diabetes, schizophrenia, asthma, RSV, and haematological malignancies Establishment and regulatory submission of key standards and tools for drug development in infectious diseases, COPD, diabetes Improved clinical trial design and process in schizophrenia, pain, autism Projects launched and planned on use of real life data and alignment of regulators and payers data requirement 15
16 Pharma industry already tackling opportunities along the value chain Research Development Public Health Market Access Medical Identification of novel target pathways by integrating diverse data sets Improvement of trials design and simulation EHR4CR Personalised prevention and targeted interventions Flexible pathways to provide early patient access MAPPs Identification of best practices to improve health outcomes and increase efficiency BD4BO Operations Integrated mechanisms to ensure consistency across the whole value chain Initiatives still fragmented in terms of scope, ownership and modalities for data governance Source: "An industry perspective on Big Data"; B. Vannieuwenhuyse; EFPIA; BCG expertise
17 Support research using health data: EMIF project overview EMIF-Metabolic EMIF-AD 57 partners from 14 European countries Identify predictors of metabolic complications in obesity Identify predictors of Alzheimer's Disease (AD) in the pre-clinical phase 56 million worth of resources Three projects in one EMIF-Platform Develop a framework for evaluating, enhancing and providing access to human health data across Europe, support EMIF-Metabolic and EMIF-AD (the specific topics above) as well as support research using human health data in general Academic Partners SME Partners Efpia Partners Patient Organisation Source: "An industry perspective on Big Data"; B. Vannieuwenhuyse; BCG expertise
18 Network of hospitals to overcome challenges in clinical development: EHR4CR Only 18% in Europe, and 7% in the US complete their enrolment on time 50% of today's clinical trials fail to achieve the target recruitment Almost 50% of all trial delays caused by patient recruitment problems 1/3 of protocol amendments are avoidable, at a cost of $0.5m Site dependent process No patient data leaves the hospitals EHR ETL CD W InSite Local Install InSite Central Platform Secure access for researchers Local InSite applications The hospital remains in control of its data EFPIA Partners Source: "An industry perspective on Big Data"; B. Vannieuwenhuyse; BCG expertise
19
20 HARMONY is currently the largest program under the IMI "Big Data for Better Outcomes" umbrella
21 The patient is at the center of HARMONY: Collaboration of all stakeholders needed to meet patients' needs Hematologists Bioinformaticians Data scientists & ICT Pharma Industry Economists Patients Policy makers Regulators HTAs Ethics
22 HARMONY aims to meet major unmet needs in HMs Need for harmonisation of outcome measures and endpoint definitions for HMs at European level Increasing omics data available, but limited application in clinical practice Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY Need for speeding up drug development, access pathways and "bench-to-bedside" process
23 Aims and Outputs Establish a clinical data-sharing platform that empowers clinicians, patients and policy stakeholders to improve decision-making Create a community of European hematological malignancies stakeholders Improve access and management of Big Data series from HM patients Define meaningful and harmonized clinical endpoints and outcomes in HMs Provide tools for analyzing complex data sets Identify biomarkers that will contribute to timely patient access to more effective and better tolerated innovative therapies Share relevant information and knowledge on HMs Provide a framework for legal, ethical and governance issues
24 Need for public-private collaboration- The EHDN
25 Objectives of the full project: You cannot change, what you do not measure The first goal of the EHDN is to implement the approaches pioneered in these earlier research projects and develop a standard methodology The second goal of EHDN is to help mature both the supply side and the demand side of this health data eco-system in compliance with robust privacy and ethics governance The third goal of EHDN is to stimulate development of new and augmented health services through available and expanded technologies, in the interest of health outcomes
26 Objectives of the full project
27 Pre-competitive nature EHDN will be conducted as per all IMI programmes in a pre-competitive environment: The programme requires diverse collaboration for the development of an underpinning data network supportive of a value-based research ecosytem for all actors in this domain: It is primarily focused on real world data and infrastructure, and not on explicit health research Data and analytical methodologies for transitioning varied real world data to real world evidence EHDN is an enabler for other BD4BO research projects
28 Expected impact of the EHDN Pivotal: Network of diverse data sources facilitating increasing requirement for real world evidence to support expanding value-based and outcomes-focused healthcare delivery in Europe Critical: Technology deployment based on prior or relevant programmes (e.g. EHR4CR, EMIF, ADVANCE, OHDSI/OMOP) to facilitate the bi-directional relationship between data custodians and data users Enablers: Evolution of research methodologies, inclusive of harmonisation, to meet the evidence challenge of value and outcomes-based care within the context of multicentre, real world, observational research
EU Big Data Initiatives
European Network of Excellence for Big Data in Hematology, consisting of 51 partners from 11 countries. Aliki Taylor, HARMONY Alliance Partner Director Global Health Outcomes, Takeda EU Big Data Initiatives
More informationInnovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
More informationBD4BO and ROADMAP: a collaborative approach to set new standards for the collation and evaluation of RWE in Alzheimer s Disease
BD4BO and ROADMAP: a collaborative approach to set new standards for the collation and evaluation of RWE in Alzheimer s Disease Impact of Big Data Analytics on Healthcare 4-5 October 2017, Luxembourg Dr
More informationPublic private partnerships in support to regulatory sciences
Public private partnerships in support to regulatory sciences The Innovative Medicines Initiative example M. Chlebus 3 October 2017 www.efpia.eu Summary: Partnering on regulatory sciences Progress much
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationFrom IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014
From IMI to IMI2 new models of collaborative research Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014 What is IMI and how does it work? Innovative Medicines Initiative: Joining Forces in the
More informationEuropean contribution to the RWD/RWE debate. Alasdair Breckenridge July 2018
European contribution to the RWD/RWE debate Alasdair Breckenridge July 2018 Sources UK Academy of Medical Sciences(AMS) workshops European Medicines Agency (EMA) Innovative Medicines Initiative (IMI) projects
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationThe European Health Data & Evidence Network
The European Health Data & Evidence Network What is it? Nigel Hughes EFPIA Coordinator Scientific Director, JCI Patient Data for Research, Janssen 18 th May 2018 1 All too often real world research is
More informationUsing local RWD to drive global therapeutic advancements.
Using local RWD to drive global therapeutic advancements. Helsinki, 30 th Nov 2016 Mike Spencer, Head of Real World Evidence, EMEA, Janssen The following represent my own views and not necessarily those
More informationThe Innovative Medicines Initiative. Pierre Meulien CNIO, Madrid - Spain
The Innovative Medicines Initiative Pierre Meulien 12.01.2017 CNIO, Madrid - Spain IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2020 Pharma industry 2.5 bn EU contribution from FP7
More informationPublic private partnerships to encourage patient access
Public private partnerships to encourage patient access 5 th SFE SFUS Conference Challenges for efficient health care in Central and Eastern Europe Belgrade, 10 th October 2015 How does IMI work? The Innovative
More information3ª MESA: QUÉ UTILIDAD OFRECE EL BIG DATA?
3ª MESA: QUÉ UTILIDAD OFRECE EL BIG DATA? Jesús M. Hernández Rivas Instituto de Investigación Biomédica de Salamanca. Universidad de Salamanca. Servicio de Hematología. Hospital Universitario de Salamanca.
More informationCoordination and Support Action (CSA) for the Big Data for Better Outcomes programme. Stephan Korte, Kim Cryns
Coordination and Support Action (CSA) for the Big Data for Better Outcomes programme Stephan Korte, Kim Cryns 11.01.2016 IMI webinar Big Data for Better Outcomes (BD4BO) Initiative within IMI2 Goal Support
More informationThe Innovative Medicines Initiative Socio-economic impacts
The Innovative Medicines Initiative Socio-economic impacts Pierre Meulien, IMI Executive Director European Innovation Summit European Parliament 08.12.2015 Closed & open innovation Filing Approval HTA
More informationThe Innovative Medicines Initiative
Joining forces to accelerate biomedical innovation The Innovative Medicines Initiative www.efpia.eu What s in IMI? In IMI the industry and the Commission are partners IMI delivers solutions for patients
More informationTHE CONVERGENCE INITIATIVE TO MAXIMISE THE VALUE FROM EUROPEAN RESEARCH
THE CONVERGENCE INITIATIVE TO MAXIMISE THE VALUE FROM EUROPEAN RESEARCH Georges De Moor EuroRec, Ghent University Electronic Health Records for Clinical Research 192 Growing number of Participating Projects
More informationJoint Technology Initiative: Innovative Medicine Initiative
Joint Technology Initiative: Innovative Medicine Initiative Dr John E Butler-Ransohoff Global External Innovation and Alliances Bayer HealthCare AG, Berlin/Wuppertal Bari, 30 April 2015 Largest Public
More informationInnovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017
Innovative Medicines Initiative (IMI) Future funding opportunities Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017 Outline What is IMI and why do we need it? How does IMI work?
More informationInnovative Medicines Initiative - the story so far
Innovative Medicines Initiative - the story so far Ruxandra Draghia-Akli MD PhD Director Health, Research & DG Health Research at a Crossroads Are Public-Private Partnerships the Way Forward? European
More informationTRANSFORMING CLINICAL RESEARCH FOR FASTER ACCESS TO INNOVATIVE MEDICINES. Establishing the Value of EHR4CR for Pharmaceutical Industry
TRANSFORMING CLINICAL RESEARCH FOR FASTER ACCESS TO INNOVATIVE MEDICINES Establishing the Value of EHR4CR for Pharmaceutical Industry BACKGROUND In the current healthcare environment, bringing a new drug
More informationNew Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
More informationWebinar IMI2 Call 13 Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
Webinar IMI2 Call 13 Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative 27.11.2017 15:00 CET Agenda How to use GoToWebinar Catherine Brett,
More informationThe Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels
The Innovative Medicines Initiative Europe s partnership for health Tek-Ang LIM, 20 June 2018, Brussels 10 YEARS OF LIGHTING THE WAY IMI Why Europe s partnership for health? Because despite decades of
More informationLeveraging Big Data for Better Health Outcomes: The Need for a Collaborative Space and Common Solutions
Leveraging Big Data for Better Health Outcomes: The Need for a Collaborative Space and Common Solutions Author: Richard Bergstrom * Date: 14.11.2016 * Version: 1 Disruption 2 Why this discussion now Definitions.
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationInnovative Medicines Initiative Sadallah Fatiha IMI JU Office, Brussels, Belgium
Innovative Medicines Initiative 2 2009-2014 Sadallah Fatiha IMI JU Office, Brussels, Belgium The Evolution of IMI: From bottlenecks in industry to bottlenecks in Industry and Society Make Drug R&D processes
More informationWebinar IMI2 Call 13 CONCEPTION continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
Webinar IMI2 Call 13 CONCEPTION continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now 11 December 2017 15:00 CET Agenda How to use GoToWebinar
More informationCase study: Challenges faced by EMIF in utilising the OMOP CDM. Johan van der Lei Erasmus Medical Center Rotterdam
Case study: Challenges faced by EMIF in utilising the OMOP CDM Johan van der Lei Erasmus Medical Center Rotterdam Outline Scaffolding EMIF and a CDM EMIF and the OMOP CDM Ongoing activities/challenges
More informationE&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015
E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015 Education adapted to demand? Declining number of students choosing science Education still
More informationNeurodegeneration and other neuroscience priorities
Potential future IMI Call topics About this document The following topics are under consideration for inclusion in future IMI Calls for proposals in the longer term. The discussions on these topics are
More informationI D C T E C H N O L O G Y S P O T L I G H T
I D C T E C H N O L O G Y S P O T L I G H T C o n f r o n t i n g C h r onic Disease at the Point of M a x i m u m I mpact January 2017 Adapted from Business Strategy: Demand for IT Services Related to
More informationUniversità Cattolica del Sacro Cuore
Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who
More informationNew WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research
New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research Hanne Bak Pedersen Programme Manager Health Technologies and Pharmaceuticals
More informationType of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
More informationWebinar IMI2 Call 14 Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
Webinar IMI2 Call 14 Development of a platform for federated and privacy-preserving machine learning in support of drug discovery 16 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Introduction
More informationInnovative Medicines Initiative:
Innovative Medicines Initiative: Opportunities for local players to become important parts of multicountry pharma innovation Nathalie Serigneuret 4 March 2015 Clinical Trials Conference 2015, Budapest
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 4/24 Record STAMP Commission Expert
More informationTopic: Genome-Environment Interactions in Inflammatory Skin Disease
Topic: Genome-Environment Interactions in Inflammatory Skin Disease All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationHARMONY: European Network of Excellence for Big Data in Hematology
European Network of Excellence for Big Data in Hematology, consisting of 51 partners from 11 countries. HARMONY: European Network of Excellence for Big Data in Hematology Barcelona, 5 de marzo de 2018
More informationPartnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC
Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives Oncology Therapeutic Area Janssen Research & Development, LLC To Our Potential Partners We offer partners the depth of
More informationEBE White Paper on Personalised Medicine
EBE White Paper on Personalised Medicine EBE is a specialised group of European Federation of Pharmaceutical Industries and Associations, EFPIA Content p3 p4 p6 p6 p7 p9 p10 p11 p13 p14 Executive Summary
More informationPartnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
More information- OMICS IN PERSONALISED MEDICINE
SUMMARY REPORT - OMICS IN PERSONALISED MEDICINE Workshop to explore the role of -omics in the development of personalised medicine European Commission, DG Research - Brussels, 29-30 April 2010 Page 2 Summary
More informationTHERAPEUTIC AREAS CARDIOVASCULAR RESEARCH
THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH PPD S CARDIOVASCULAR TEAM: OPTIMIZING TRIALS AND IMPROVING OUTCOMES APPLYING EXPERIENCE, INNOVATION AND EFFICIENCY IN THE FIGHT AGAINST CARDIOVASCULAR DISEASE
More informationPAREXEL ACCESS MANAGED ACCESS PROGRAMS
PAREXEL ACCESS MANAGED ACCESS PROGRAMS Demands are increasing on biopharmaceutical companies developing treatments for unmet diseases to make them available to select patients even before the drug is labeled,
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationFDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development. October 4, 2004
FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development October 4, 2004 1 What is the problem? Trends in Biomedical Research Spending R&D Spending Has Accelerated Since 1990
More informationAIFA s post-marketing registries and accelerated patient access. Opportunities and challenges in the context of MAPPs
AIFA s post-marketing registries and accelerated patient access. Opportunities and challenges in the context of MAPPs Entela Xoxi Can RWD accelerate patient access to medicines? London, 7th July 2016 Since
More informationIntroduction to IMI. Pierre Meulien Executive Director Innovative Medicines Initiative
Introduction to IMI Pierre Meulien Executive Director Innovative Medicines Initiative What is the Innovative Medicines Initiative? EU funding goes to: - universities - SMEs - patient groups etc 2.5 bn
More informationInnovative Medicines Initiative Personalised Medicine Cancer and Diabetic Research. Krakow Biotechnology congress - 13 October 2011
Innovative Medicines Initiative Personalised Medicine Cancer and Diabetic Research Krakow Biotechnology congress - 13 October 2011 Fatiha Sadallah IMI Scientific Manager What is the Innovative Medicines
More informationBeyond Real World Evidence
Beyond Real World Evidence How to improve utilisation of Real World Data throughout an organisation Real World Evidence (RWE) has demonstrated real business value by enabling medical researchers to analyse
More informationThe International Consortium for Personalised Medicine
The International Consortium for Personalised Medicine Mairead O Driscoll Alliance for Biomedical Research in Europe, 8 November 2017 Personalised Medicine A definition Characterisation of individuals
More informationIMI: A Public Private Partnership Funder
IMI: A Public Private Partnership Funder 25-26 July 2011, European Medicines Agency Transatlantic workshop: Drug-related Progressive Multifocal Leukoencephalopathy The Innovative Medicines Initiative (IMI):
More informationThe NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England
The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.
More informationWebinar IMI2 Call 14 Opportunities for SMEs
Webinar IMI2 Call 14 Opportunities for SMEs 19 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Opportunities for SMEs Colm Carroll, IMI Questions & answers How to use GoToWebinar - audio
More information2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award
2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award 2018 2018 NORTH AMERICAN REAL-WORLD EVIDENCE ENTERPRISE SOLUTIONS MARKET LEADERSHIP AWARD Contents Background and Company
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/6/242/242cm6/dc1 Supplementary Materials for Sandbox: Building and Sharing Resources This PDF file includes: Mark David Lim E-mail: mlim@fastercures.org
More informationWhat IMI means for POLAND
What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)
More informationThe Future of Market Access A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationHELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY
HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT PPD IS A PARTNER WITH PROVEN CAPABILITIES THAT SUPPORT AND ADVANCE ONCOLOGY RESEARCH
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationMoving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment
Moving HTA forward: The challenges of incorporating real world evidence into Health Technology Assessment Matthias Egger Mike Chambers Univ. of Berne, Switzerland GSK, UK Slide 1 Increasingly complex external
More informationInnovation in medical devices as response to Europe's healthcare challenges. Industry's viewpoint
HIGH-LEVEL CONFERENCE "EXPLORING INNOVATIVE HEALTHCARE THE ROLE OF MEDICAL TECHNOLOGY INNOVATION AND REGULATION" Innovation in medical devices as response to Europe's healthcare challenges Industry's viewpoint
More informationCoordination and Support Action: Enabling platform on medicines adaptive pathways to patients
Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients Solange Rohou (AZ) & Luk Maes (BMS) 17.12.2014 IMI webinar Content Background information CSA project proposal
More informationECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie)
ECO-PHARMACO- STEWARDSHIP (EPS) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT OF PHARMACEUTICALS IN THE ENVIRONMENT (ipie) PILLAR 1 - RESEARCH & DEVELOPMENT: INTELLIGENCE-LED ASSESSMENT
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationFollowing Cancer Drug Pathways from Inception to Launch: Partnership, prospects and Pitfalls. Katie Pascoe (Value and Access, ABPI) 22 September 2016
Following Cancer Drug Pathways from Inception to Launch: Partnership, prospects and Pitfalls Katie Pascoe (Value and Access, ABPI) 22 September 2016 Partnering is a key factor in patient access to new
More informationPanel Discussion on New Business Models
Panel Discussion on New Business Models Mats Sundgren, Moderator Coordinator of the European Innovative Medicine Initiative EHR4CR project, AstraZeneca Danielle Dupont Chief Scientific Officer, Data Mining
More informationCreation of a pan-european Paediatric Clinical Trials Network. Heidrun Hildebrand (Bayer) & William Treem (Janssen),
Creation of a pan-european Paediatric Clinical Trials Network Heidrun Hildebrand (Bayer) & William Treem (Janssen), 19.12.2016 IMI webinar Need for public-private collaboration Due to European Regulation,
More informationNew Frontiers in Personalized Medicine
New Frontiers in Personalized Medicine Oracle Open World Shanghai 2013 Neil de Crescenzo SVP and GM 1 Safe Harbor Statement The following is intended to outline our general product direction. It is intended
More informationRWE Market Impact on Medicines: A Lens for Pharma
EXECUTIVE SUMMARY RWE Market Impact on Medicines: A Lens for Pharma An international comparison of the use and impact of Real World Evidence The pharmaceutical industry s increasing focus on RWE reflects
More informationehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014
ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014 Health care is in the middle of a perfect storm Changing demographics Unmet needs
More informationMaking the case for Personalised Medicine
Making the case for Personalised Medicine The biopharmaceutical industry perspective Barbara Freischem Executive Director European Biopharmaceutical Enterprises Who we are EBE represents the voice of biopharmaceutical
More informationEuropean Induced Pluripotent Stem Cell Bank
European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented
More informationAccelerated Development of Appropriate Patient Therapies
Accelerated Development of Appropriate Patient Therapies A Sustainable, Multi-stakeholder Approach for MAPPS - Medicines Adaptive Pathways to Patients André Broekmans Coordinator Adapt Smart Work Package
More informationPrecision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective
Precision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective December 12 th, 2017 Dr. Tim Wintermantel Real World Insights Lead, Switzerland Copyright 2017 IQVIA. All rights
More informationSection I: Creating a more Transparent and Predictable Environment for Innovation to Continue Improving People s Health Worldwide
SUPPLEMENT on HEALTHCARE INNOVATION 54th U.S.-Japan Business Conference The U.S.-Japan Business Council / Japan-U.S. Business Council November 3, 2017 Executive Summary Section I: Creating a more Transparent
More informationEvaluation of the Prime Partnership between Accelence and Quintiles. James Brook Senior Director, Head Site Management Western Europe, Quintiles
Evaluation of the Prime Partnership between Accelence and Quintiles James Brook Senior Director, Head Site Management Western Europe, Quintiles Copyright 2013 Quintiles Revised July 2013 7 BILLION HUMANS
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationAustralian Medical Research and Innovation Priorities Determination 2018
Australian Medical Research and Innovation Priorities 2018 2020 Determination 2018 I, Ian Frazer, Chair of the Australian Medical Research Advisory Board, make the following instrument on behalf of the
More informationEMA - Early Access. PEARRL Annual Meeting 2017-Regulatory Science Symposium. University College Cork, Ireland
EMA - Early Access PEARRL Annual Meeting 2017-Regulatory Science Symposium University College Cork, Ireland Presented by Evangelos Kotzagiorgis Scientific Administrator, Quality of Medicines Office Specialised
More informationEMA Support to Innovation: Operation of the EU Innovation Network
EMA Support to Innovation: Operation of the EU Innovation Network 2 nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency Presented by Marisa Papaluca
More informationFramework for FDA s Real-World Evidence Program
Framework for FDA s Real-World Evidence Program Jacqueline Corrigan-Curay, J.D., M.D. Director, Office of Medical Policy Center for Drug Evaluation and Research Food and Drug Administration March 15, 2019
More informationA European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative
More informationMAKING OUTCOME-BASED PAYMENTS A REALITY IN THE NHS RESEARCH STUDY: PHASE INTRODUCTION. Research Brief
MAKING OUTCOME-BASED PAYMENTS A REALITY IN THE NHS RESEARCH STUDY: PHASE 1 1.0 INTRODUCTION Cancer Research UK (CRUK) believes cancer patients should have access to the best, evidence-based innovative
More informationPan European Paediatric Clinical Trials Network From idea to realization
Pan European Paediatric Clinical Trials Network From idea to realization Heidrun Hildebrand, Bayer Ag Mark Turner, University of Liverpool 2 Nordic Pediatric Conference Helsinki, May 21/22, 2018 This project
More informationKPI Definition Comment Relates to Baseline Target
IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year
More informationDeveloping Drugs for Rare Diseases: Patient Advocacy s Perspective. Kristina Bowyer Executive Director, Patient Advocacy
Developing Drugs for Rare Diseases: Patient Advocacy s Perspective Kristina Bowyer Executive Director, Patient Advocacy February 5, 2018 An Advocacy Perspective Why develop drugs for Rare Disease? What
More informationWebinar IMI2 - Call 15 Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease
Webinar IMI2 - Call 15 Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease 09.07.2018 Agenda How to use GoToWebinar Catherine Brett, IMI Introduction Iwona Jablonska,
More informationPersonalised Medicine Regulatory Issues
Personalised Medicine Regulatory Issues INFRAFRONTIER / IMPC Stakeholder Meeting Presented by Marisa Papaluca on 14 November 2017 Senior Scientific Advisor, Scientific Committees Regulatory Science Strategy
More informationMedivir Corporate Presentation December, A research-based pharmaceutical company focused on infectious diseases and oncology
Medivir Corporate Presentation December, 2015 A research-based pharmaceutical company focused on infectious diseases and oncology 2 Balanced platform of innovation and revenue generation Locations and
More informationThe Integration of Market Access and Advocacy: The Changing Landscape OCTOBER 2016
The Integration of Market Access and Advocacy: The Changing Landscape OCTOBER 2016 The Integration of Market Access and Advocacy: The Changing Landscape Introduction Healthcare market access and advocacy
More informationBelgium, a European leader in clinical trials
Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials
More informationThe importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016
The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016 Marianne Kock, Head of Global Regulatory Affairs & Managing Director, Ferring Pharmaceuticals
More informationWorking Together for Better Health Partnering with Boehringer Ingelheim. JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017
Working Together for Better Health Partnering with Boehringer Ingelheim JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017 Welcome to Partnering with Boehringer Ingelheim Our guiding principle Value
More informationResearch and development case study. Human health research
Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published
More information